Abstract 245P
Background
Dedifferentiated endometrial carcinoma (DDEC) and undifferentiated endometrial carcinoma (UDEC) are uncommon but exhibit aggressive clinical courses. Recent studies reported the loss of expression of SMARCB1 (INI1), SMARCA4 (BRG1), or ARID1A and ARID1B, core or DNA-binding subunits of switch/sucrose non-fermenting (SWI/SNF) complex, resulted in inactivation of SWI/SNF complex that was related to dedifferentiation of endometrial carcinoma.
The efficacy of platinum-based chemotherapy that is standard care for differentiated endometrial carcinoma is still unknown for UDEC and DDEC.
Methods
Thirteen patients diagnosed with UDEC or DDEC at our institute between 1999 and 2019 were included in this retrospective study. Inactivation of SWI/SNF complex was defined as deficiencies in expression of either INI1, BRG1, or ARID1A and ARID1B. Mismatch repair (MMR) status was also confirmed by immunohistochemistry. We evaluated clinical features and outcome in UDEC and DDEC.
Results
The median age at diagnosis was 54 years (range, 47-61). 2/5/6 patients presented with stage I/III/IV disease, respectively. Loss of INI1/BRG1/ARID1A and ARID1B was observed in 1/5/8 patients. Of the 11 patients whose MMR status were evaluated, 9 (82%) were identified as MMR deficient. Two patients underwent surgery alone because of early stage. Three patients received platinum-based chemotherapy as adjuvant therapy, and none of them has relapsed. Of the 8 patients who were unresectable or incompletely resected, 3 patients received platinum-based chemotherapy (doxorubicin/cisplatin or paclitaxel/carboplatin), 4 patients did not due to poor PS, and 1 patient did other regimen. In patients with unresectable or incompletely resected disease with platinum-based chemotherapy, response rate (RR), median progression free survival, and median overall survival (mOS) were 100%, 9.1 months, and 18.6 months, respectively. In patients with unresectable or incompletely resected disease without platinum-based chemotherapy, mOS was 2.7 months.
Conclusions
Platinum-based chemotherapy showed high RR for UDEC and DDEC. We will report case presentation about a few cases with specific clinical courses.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session